IL-33 signaling contributes to the pathogenesis of myeloproliferative neoplasms

Journal of Clinical Investigation

Volumn 125, Issue 7, 2015, Pages 2579-2591

  Mager, Lukas F ^a,b   Riether, Carsten ^b   Schürch, Christian M ^a,b   Banz, Yara ^a   Wasmer, Marie Hélene ^a   Stuber, Regula ^a   Theocharides, Alexandre P ^c   Li, Xiaohong ^d   Xia, Yu ^e   Saito, Hirohisa ^f   Nakae, Susumu ^f   Baerlocher, Gabriela M ^b   Manz, Markus G ^c   McCoy, Kathy D ^b   Macpherson, Andrew J ^b,g   Ochsenbein, Adrian F ^b,g   Beutler, Bruce ^d   Krebs, Philippe ^a  

^a UNIVERSITY OF BERN   (Switzerland)

^b UNIVERSITY OF BERN   (Switzerland)

^c UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^d UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^e SCRIPPS RESEARCH INSTITUTE   (United States)

^f NATIONAL RESEARCH INSTITUTE FOR CHILD HEALTH AND DEVELOPMENT   (Japan)

^g UNIVERSITY OF BERN   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 33; JANUS KINASE 2; MYELOID DIFFERENTIATION FACTOR 88; SYNAPTOJANIN; CARRIER PROTEIN; IL1RL1 PROTEIN, MOUSE; IL33 PROTEIN, HUMAN; INOSITOL-POLYPHOSPHATE 5-PHOSPHATASE; INTERLEUKIN 1 RECEPTOR ASSOCIATED KINASE; INTERLEUKIN DERIVATIVE; INTERLEUKIN RECEPTOR; INTERLEUKIN-33, MOUSE; IRAK4 PROTEIN, MOUSE; JAK2 PROTEIN, MOUSE; MUTANT PROTEIN; MYD88 PROTEIN, MOUSE; PHOSPHATASE; STYX PROTEIN, MOUSE; TOLL LIKE RECEPTOR;

ALLELE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BONE MARROW CELL; COLONY FORMATION; CYTOKINE PRODUCTION; CYTOKINE RELEASE; HEMATOPOIESIS; HEMATOPOIETIC CELL; HUMAN; HUMAN CELL; MOUSE; MYELOID PROGENITOR CELL; MYELOPOIESIS; MYELOPROLIFERATIVE DISORDER; MYELOPROLIFERATIVE NEOPLASM; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; STEADY STATE; STEM CELL; STROMA CELL; ANIMAL; C57BL MOUSE; DEFICIENCY; DISEASE MODEL; GENETICS; IMMUNOLOGY; KNOCKOUT MOUSE; MALE; METABOLISM; MUTANT MOUSE STRAIN; MYELOPROLIFERATIVE DISORDERS; PHYSIOLOGY; SIGNAL TRANSDUCTION; TRANSGENIC MOUSE;

ANIMALS; CARRIER PROTEINS; DISEASE MODELS, ANIMAL; HUMANS; INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASES; INTERLEUKINS; JANUS KINASE 2; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MICE, MUTANT STRAINS; MICE, TRANSGENIC; MUTANT PROTEINS; MYELOID DIFFERENTIATION FACTOR 88; MYELOPOIESIS; MYELOPROLIFERATIVE DISORDERS; PHOSPHORIC MONOESTER HYDROLASES; RECEPTORS, INTERLEUKIN; SIGNAL TRANSDUCTION; TOLL-LIKE RECEPTORS;

EID: 84936761972     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI77347     Document Type: Article

References (49)

1. Wadleigh M, Tefferi A. Classification and diagnosis of myeloproliferative neoplasms according to the 2008 World Health Organization criteria. Int J Hematol. 2010;91(2):174-179.
2. Jedidi A, et al. Selective reduction of JAK2V617F-dependent cell growth by siRNA/ shRNA and its reversal by cytokines. Blood. 2009;114(9):1842-1851.
3. Jiang X, Lopez A, Holyoake T, Eaves A, Eaves C. Autocrine production and action of IL-3 and granulocyte colony-stimulating factor in chronic myeloid leukemia. Proc Natl Acad Sci U S A. 1999;96(22):12804-12809.
4. Reynaud D, et al. IL-6 controls leukemic multipotent progenitor cell fate and contributes to chronic myelogenous leukemia development. Cancer Cell. 2011;20(5):661-673.
5. Gallipoli P, et al. Autocrine TNF-alpha production supports CML stem and progenitor cell survival and enhances their proliferation. Blood. 2013;122(19):3335-3339.
6. Corbin AS, Agarwal A, Loriaux M, Cortes J, Deininger MW, Druker BJ. Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity. J Clin Invest. 2011;121(1):396-409.
7. Bhagwat N, Levine RL, Koppikar P. Sensitivity and resistance of JAK2 inhibitors to myeloproliferative neoplasms. Int J Hematol. 2013;97(6):695-702.
8. Skov V, et al. Molecular profiling of peripheral blood cells from patients with polycythemia vera and related neoplasms: identification of deregulated genes of significance for inflammation and immune surveillance. Leuk Res. 2012;36(11):1387-1392.
9. Fleischman AG, et al. TNFα facilitates clonal expansion of JAK2V617F positive cells in myeloproliferative neoplasms. Blood. 2011;118(24):6392-6398.
10. Hasselbalch HC. The role of cytokines in the initiation and progression of myelofibrosis. Cytokine Growth Factor Rev. 2013;24(2):133-145.
11. Manshouri T, et al. Bone marrow stroma-secreted cytokines protect JAK2(V617F)-mutated cells from the effects of a JAK2 inhibitor. Cancer Res. 2011;71(11):3831-3840.
12. Kristinsson SY, Bjorkholm M, Hultcrantz M, Derolf AR, Landgren O, Goldin LR. Chronic immune stimulation might act as a trigger for the development of acute myeloid leukemia or myelodysplastic syndromes. J Clin Oncol. 2011;29(21):2897-2903.
13. Anderson LA, Pfeiffer RM, Landgren O, Gadalla S, Berndt SI, Engels EA. Risks of myeloid malignancies in patients with autoimmune conditions. Br J Cancer. 2009;100(5):822-828.
14. Titmarsh GJ, McMullin MF, McShane CM, Clarke M, Engels EA, Anderson LA. Community-acquired infections and their association with myeloid malignancies. Cancer Epidemiol. 2014;38(1):56-61.
15. Fleischman AG, et al. Exaggerated response to toll-like receptor agonist contributes to excessive TNF production in myeloproliferative neoplasm. Blood. 2013;122(21):4097.
16. Liew FY, Pitman NI, McInnes IB. Disease-associated functions of IL-33: The new kid in the IL-1 family. Nat Rev Immunol. 2010;10(2):103-110.
17. Pichery M, et al. Endogenous IL-33 is highly expressed in mouse epithelial barrier tissues, lymphoid organs, brain, embryos, and inflamed tissues: in situ analysis using a novel Il-33-LacZ gene trap reporter strain. J Immunol. 2012;188(7):3488-3495.
18. Pastorelli L, et al. Epithelial-derived IL-33 and its receptor ST2 are dysregulated in ulcerative colitis and in experimental Th1/Th2 driven enteritis. Proc Natl Acad Sci U S A. 2010;107(17):8017-8022.
19. Bonilla WV, et al. The alarmin interleukin-33 drives protective antiviral CD8(+) T cell responses. Science. 2012;335(6071):984-989.
20. Byers DE, et al. Long-term IL-33-producing epithelial progenitor cells in chronic obstructive lung disease. J Clin Invest. 2013;123(9):3967-3982.
21. Croker BA, et al. Inflammation and autoimmunity caused by a SHP1 mutation depend on IL-1, MyD88, and a microbial trigger. Proc Natl Acad Sci U S A. 2008;105(39):15028-15033.
22. Rivas MN, et al. MyD88 is critically involved in immune tolerance breakdown at environmental interfaces of Foxp3-deficient mice. J Clin Invest. 2012;122(5):1933-1947.
23. Helgason CD, et al. Targeted disruption of SHIP leads to hemopoietic perturbations, lung pathology, and a shortened life span. Genes Dev. 1998;12(11):1610-1620.
24. Liu Q, et al. SHIP is a negative regulator of growth factor receptor-mediated PKB/Akt activation and myeloid cell survival. Genes Dev. 1999;13(7):786-791.
25. Wang JW, et al. Influence of SHIP on the NK repertoire and allogeneic bone marrow transplantation. Science. 2002;295(5562):2094-2097.
26. Wilson A, et al. Dormant and self-renewing hematopoietic stem cells and their niches. Ann N Y Acad Sci. 2007;1106:64-75.
27. Pinho S, et al. PDGFRalpha and CD51 mark human nestin+ sphere-forming mesenchymal stem cells capable of hematopoietic progenitor cell expansion. J Exp Med. 2013;210(7):1351-1367.
28. Maeda K, et al. IL-6 blocks a discrete early step in lymphopoiesis. Blood. 2005;106(3):879-885.
29. Hazen AL, Smith MJ, Desponts C, Winter O, Moser K, Kerr WG. SHIP is required for a functional hematopoietic stem cell niche. Blood. 2009;113(13):2924-2933.
30. Kubovcakova L, et al. Differential effects of hydroxyurea and INC424 on mutant allele burden and myeloproliferative phenotype in a JAK2-V617F polycythemia vera mouse model. Blood. 2013;121(7):1188-1199.
31. Allakhverdi Z, et al. CD34+ hemopoietic progenitor cells are potent effectors of allergic inflammation. J Allergy Clin Immunol. 2009;123(2):472-478.
32. Meephansan J, Tsuda H, Komine M, Tominaga S, Ohtsuki M. Regulation of IL-33 expression by IFN-γ and tumor necrosis factor-α in normal human epidermal keratinocytes. J Invest Dermatol. 2012;132(11):2593-2600.
33. Kouzaki H, Iijima K, Kobayashi T, O'Grady SM, Kita H. The danger signal, extracellular ATP, is a sensor for an airborne allergen and triggers IL-33 release and innate Th2-type responses. J Immunol. 2011;186(7):4375-4387.
34. Gangemi S, et al. Decreased plasma levels of IL-33 could contribute to the altered function of Th2 lymphocytes in patients with polycythemia vera and essential thrombocythemia. Cancer Invest. 2013;31(3):212-213.
35. Singh VK, Fatanmi OO, Singh PK, Whitnall MH. Role of radiation-induced granulocyte colonystimulating factor in recovery from whole body gamma-irradiation. Cytokine. 2012;58(3):406-414.
36. Ha CT, et al. Circulating interleukin-18 as a biomarker of total-body radiation exposure in mice, minipigs, and nonhuman primates (NHP). PLoS One. 2014;9(10):e109249.
37. Levescot A, et al. BCR-ABL-induced deregulation of the IL-33/ST2 pathway in CD34(+) progenitors from chronic myeloid leukemia patients. Cancer Res. 2014;74(10):2669-2676.
38. Jiang X, et al. Primitive interleukin 3 null hematopoietic cells transduced with BCR-ABL show accelerated loss after culture of factor-independence in vitro and leukemogenic activity in vivo. Blood. 2002;100(10):3731-3740.
39. Ali S, et al. The dual function cytokine IL-33 interacts with the transcription factor NF-κB to dampen NF-κB-stimulated gene transcription. J Immunol. 2011;187(4):1609-1616.
40. Choi YS, et al. Interleukin-33 induces angiogenesis and vascular permeability through ST2/ TRAF6-mediated endothelial nitric oxide production. Blood. 2009;114(14):3117-3126.
41. Medinger M, et al. Angiogenesis and vascular endothelial growth factor-/receptor expression in myeloproliferative neoplasms: correlation with clinical parameters and JAK2-V617F mutational status. Br J Haematol. 2009;146(2):150-157.
42. Hoebe K, et al. Identification of Lps2 as a key transducer of MyD88-independent TIR signalling. Nature. 2003;424(6950):743-748.
43. Oboki K, et al. IL-33 is a crucial amplifier of innate rather than acquired immunity. Proc Natl Acad Sci U S A. 2010;107(43):18581-18586.
44. Townsend MJ, Fallon PG, Matthews DJ, Jolin HE, McKenzie AN. T1/ST2-deficient mice demonstrate the importance of T1/ST2 in developing primary T helper cell type 2 responses. J Exp Med. 2000;191(6):1069-1076.
45. Tiedt R, et al. Ratio of mutant JAK2-V617F to wild-type Jak2 determines the MPD phenotypes in transgenic mice. Blood. 2008;111(8):3931-3940.
46. Cheng CC, et al. Isolation and characterization of novel murine epiphysis derived mesenchymal stem cells. PLoS One. 2012;7(4):e36085.
47. Ullman-Cullere MH, Foltz CJ. Body condition scoring: A rapid and accurate method for assessing health status in mice. Lab Anim Sci. 1999;49(3):319-323.
48. Paster EV, Villines KA, Hickman DL. Endpoints for mouse abdominal tumor models: refinement of current criteria. Comp Med. 2009;59(3):234-241.
49. Xiao W, Hong H, Kawakami Y, Lowell CA, Kawakami T. Regulation of myeloproliferation and M2 macrophage programming in mice by Lyn/Hck, SHIP, and Stat5. J Clin Invest. 2008;118(3):924-934.